Vyome Holdings, Inc (HIND)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.97
- As of
Kresmion compiles this page from HIND's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vyome Holdings, Inc (HIND): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-28.
See the full HIND dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HIND on one page. Preview it with sample data, then open it live with a free account.
Preview the HIND dossierActive signals for HIND
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in HIND
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 48.4%, EPS $-0.10 vs $-0.1938 estimate
- mediumEARNINGS_BEAT
Q4-2023: Beat consensus by 39.9% - EPS $-639.624 vs $-1064.88 estimate
- mediumEARNINGS_BEAT
Q1-2024: Beat consensus by 44.9% - EPS $-522 vs $-946.56 estimate
- mediumEARNINGS_BEAT
Beat consensus by 39.9% - EPS $-639.624 vs $-1064.88 estimate
FREE, NO ACCOUNT
Every signal on HIND, as it fires
You are seeing 5 of 8 signals recorded on HIND since 2026-05-29.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in HIND (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 92943X104 · 2026Q2 | $56K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, HIND
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HIND against its peers
HIND's operating margin of -3269.4% ranks in the 55th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | HIND | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 319714 USD | 668000 USD | 41 | 10 |
| Gross margin | 68.4% | n/a | n/a | 4 |
| Operating margin | -3269.4% | -3939.1% | 55 | 9 |
| Net margin | -3209.7% | -2927.1% | 50 | 10 |
| Return on equity | -272.8% | -113.0% | 13 | 18 |
| 1 year | n/a | -58.0% | n/a | 14 |
Peers (22): LSTA, SYBX, AEON, CKDXF, TPST, PASG, INAB, LTRN, ANEB, PLUR, BIVI, ASBP, KTTA, TVRD, GDTC, HEPA, ICU, VTGN, CYCN, CLRB, BLRX, ALLR. Left out: VICP (period gap), HOOK (period gap), CTXR (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (HIND: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HIND on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HIND for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.